Improving the efficacy of cancer immunotherapy by host-defence caerin 1.1 and 1.9 peptides
Cancer remains a major global health challenge. Immunotherapy has revolutionized the management of cancer, yet only a limited number of patients respond to such treatments. This is largely attributed to the immunosuppressive tumor microenvironment, which diminishes the effectiveness of immunotherapy...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2385654 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849717338992017408 |
|---|---|
| author | Quanlan Fu Yuandong Luo Junjie Li Pingping Zhang Shuxian Tang Xinyi Song Jiawei Fu Mengqi Liu Rongmi Mo Ming Wei Hejie Li Xiaosong Liu Tianfang Wang Guoying Ni |
| author_facet | Quanlan Fu Yuandong Luo Junjie Li Pingping Zhang Shuxian Tang Xinyi Song Jiawei Fu Mengqi Liu Rongmi Mo Ming Wei Hejie Li Xiaosong Liu Tianfang Wang Guoying Ni |
| author_sort | Quanlan Fu |
| collection | DOAJ |
| description | Cancer remains a major global health challenge. Immunotherapy has revolutionized the management of cancer, yet only a limited number of patients respond to such treatments. This is largely attributed to the immunosuppressive tumor microenvironment, which diminishes the effectiveness of immunotherapy. Recent studies have underscored the potential of naturally derived caerin 1 peptides, particularly caerin 1.1 and caerin 1.9, which exhibit strong antitumor effects and enhance the efficacy of immunotherapies in animal models. This review encapsulates the current research aimed at augmenting the effectiveness of immunotherapy, focusing on the role of caerin 1.1 and caerin 1.9 in boosting immunotherapeutic outcomes, elucidating possible mechanisms, and discussing their limitations and challenges. |
| format | Article |
| id | doaj-art-2cf9809c19ac4dd58beb724a6d8729b5 |
| institution | DOAJ |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-2cf9809c19ac4dd58beb724a6d8729b52025-08-20T03:12:41ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2024-12-0120110.1080/21645515.2024.2385654Improving the efficacy of cancer immunotherapy by host-defence caerin 1.1 and 1.9 peptidesQuanlan Fu0Yuandong Luo1Junjie Li2Pingping Zhang3Shuxian Tang4Xinyi Song5Jiawei Fu6Mengqi Liu7Rongmi Mo8Ming Wei9Hejie Li10Xiaosong Liu11Tianfang Wang12Guoying Ni13Medical School of Guizhou University, Guiyang, Guizhou, ChinaMedical School of Guizhou University, Guiyang, Guizhou, ChinaR&D Department, Zhongao Bio-pharmaceutical Technology Co., Ltd., Zhongshan, Guangdong Province, ChinaCancer Research Institute, The First People’s Hospital of Foshan, Foshan, Guangdong, ChinaCancer Research Institute, The First People’s Hospital of Foshan, Foshan, Guangdong, ChinaThe First Affiliated Hospital/Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, Guangdong, ChinaThe First Affiliated Hospital/Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, Guangdong, ChinaMedical School of Guizhou University, Guiyang, Guizhou, ChinaThe First Affiliated Hospital/Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, Guangdong, ChinaSchool of Medical Sciences, Griffith University, Gold Coast, QLD, AustraliaCentre for Bioinnovation, University of the Sunshine Coast, Maroochydore BC, QLD, AustraliaR&D Department, Zhongao Bio-pharmaceutical Technology Co., Ltd., Zhongshan, Guangdong Province, ChinaCentre for Bioinnovation, University of the Sunshine Coast, Maroochydore BC, QLD, AustraliaR&D Department, Zhongao Bio-pharmaceutical Technology Co., Ltd., Zhongshan, Guangdong Province, ChinaCancer remains a major global health challenge. Immunotherapy has revolutionized the management of cancer, yet only a limited number of patients respond to such treatments. This is largely attributed to the immunosuppressive tumor microenvironment, which diminishes the effectiveness of immunotherapy. Recent studies have underscored the potential of naturally derived caerin 1 peptides, particularly caerin 1.1 and caerin 1.9, which exhibit strong antitumor effects and enhance the efficacy of immunotherapies in animal models. This review encapsulates the current research aimed at augmenting the effectiveness of immunotherapy, focusing on the role of caerin 1.1 and caerin 1.9 in boosting immunotherapeutic outcomes, elucidating possible mechanisms, and discussing their limitations and challenges.https://www.tandfonline.com/doi/10.1080/21645515.2024.2385654Caerin 1 peptideimmune checkpoint blockadetherapeutic vaccinetumor microenvironmentmacrophage |
| spellingShingle | Quanlan Fu Yuandong Luo Junjie Li Pingping Zhang Shuxian Tang Xinyi Song Jiawei Fu Mengqi Liu Rongmi Mo Ming Wei Hejie Li Xiaosong Liu Tianfang Wang Guoying Ni Improving the efficacy of cancer immunotherapy by host-defence caerin 1.1 and 1.9 peptides Human Vaccines & Immunotherapeutics Caerin 1 peptide immune checkpoint blockade therapeutic vaccine tumor microenvironment macrophage |
| title | Improving the efficacy of cancer immunotherapy by host-defence caerin 1.1 and 1.9 peptides |
| title_full | Improving the efficacy of cancer immunotherapy by host-defence caerin 1.1 and 1.9 peptides |
| title_fullStr | Improving the efficacy of cancer immunotherapy by host-defence caerin 1.1 and 1.9 peptides |
| title_full_unstemmed | Improving the efficacy of cancer immunotherapy by host-defence caerin 1.1 and 1.9 peptides |
| title_short | Improving the efficacy of cancer immunotherapy by host-defence caerin 1.1 and 1.9 peptides |
| title_sort | improving the efficacy of cancer immunotherapy by host defence caerin 1 1 and 1 9 peptides |
| topic | Caerin 1 peptide immune checkpoint blockade therapeutic vaccine tumor microenvironment macrophage |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2024.2385654 |
| work_keys_str_mv | AT quanlanfu improvingtheefficacyofcancerimmunotherapybyhostdefencecaerin11and19peptides AT yuandongluo improvingtheefficacyofcancerimmunotherapybyhostdefencecaerin11and19peptides AT junjieli improvingtheefficacyofcancerimmunotherapybyhostdefencecaerin11and19peptides AT pingpingzhang improvingtheefficacyofcancerimmunotherapybyhostdefencecaerin11and19peptides AT shuxiantang improvingtheefficacyofcancerimmunotherapybyhostdefencecaerin11and19peptides AT xinyisong improvingtheefficacyofcancerimmunotherapybyhostdefencecaerin11and19peptides AT jiaweifu improvingtheefficacyofcancerimmunotherapybyhostdefencecaerin11and19peptides AT mengqiliu improvingtheefficacyofcancerimmunotherapybyhostdefencecaerin11and19peptides AT rongmimo improvingtheefficacyofcancerimmunotherapybyhostdefencecaerin11and19peptides AT mingwei improvingtheefficacyofcancerimmunotherapybyhostdefencecaerin11and19peptides AT hejieli improvingtheefficacyofcancerimmunotherapybyhostdefencecaerin11and19peptides AT xiaosongliu improvingtheefficacyofcancerimmunotherapybyhostdefencecaerin11and19peptides AT tianfangwang improvingtheefficacyofcancerimmunotherapybyhostdefencecaerin11and19peptides AT guoyingni improvingtheefficacyofcancerimmunotherapybyhostdefencecaerin11and19peptides |